Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

KZIA
Kazia Therapeutics Limited
stock NASDAQ ADR

At Close
Jun 18, 2025 3:59:30 PM EDT
8.92USD-4.394%(-0.41)99,736
0.00Bid   0.00Ask   0.00Spread
Pre-market
Jun 18, 2025 8:00:30 AM EDT
9.15USD-1.929%(-0.18)145
After-hours
Jun 16, 2025 4:17:30 PM EDT
9.05USD-1.093%(-0.10)0
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsDividendsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsMore
open chart   
open chart   
Market Cap
12.11M
Headquarters
NSW, AUS
Industry
Biotechnology
Last Dividend
Jan 28, 20134.093
Last Split
Apr 17, 20251for5reverse
Related
ADMPRANXLV
KZIA Stats
Avg. Vol. 10 Day
5,171,195
Avg. Vol. 30 Day
1,740,331
Market Cap
12,114,259
Shares Out.
1,359,625
On/Off Exchange
53%/47%
6 Month Beta
1.02
1 Year Beta
1.54
2 Year Beta
1.24
3 Year Beta
0.57
52 Week Low
2.86
52 Week High
79.00
SMA50
4.45
SMA200
12.28
1 Week
-8.99%
1 Month
+144.78%
3 Month
+84.66%
6 Month
-41.19%
1 Year
-34.00%
2 Year
-85.86%
5 Year
-94.55%
Profile
innovative. focused. agile. kazia therapeutics is an agile, oncology-focused biotechnology company, based in sydney, australia. we have two clinical staged drug development candidates and an early stage discovery program, across a range of oncology indications. our lead program is gdc-0084, a small molecule inhibitor of the pi3k / akt / mtor pathway, which is being developed to treat glioblastoma multiforme, the primary and most aggressive form of brain cancer. licensed from genentech in late 2016, gdc-0084 is anticipated to enter phase ii clinical trials in 2017. trxe-002-1, or cantrixil is kazia's second drug development candidate under development as a treatment for ovarian cancer. the chemotherapeutic is currently undergoing a phase 1 clinical trial in hospitals across australia and the united states. initial data on this trial is expected to be reported early in 2018. kazia therapeutics is trading under the following tickers: asx: kza nasdaq: kzia for more information, please visi

KZIA Stock Summary

Kazia Therapeutics Limited (NASDAQ:KZIA) stock price today is $8.92, and today's volume is 99,736. KZIA is down -4.394% today. The 30 day average volume is 1,740,331. KZIA market cap is 12.11M with 1,359,625 shares outstanding.



Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC